Aclaris Therapeutics acquires privately held biotechnology company
Insight Weekly: Bank mergers of equals return; energy tops S&P 500; green bond sales to rise
Insight Weekly: US companies boost liquidity; auto insurers hike rates; office sector risk rises
Essential IR Insights Newsletter - Summer July-August 2023
Insight Weekly: Climate law faces hurdles; US borrowing surges; banks revise uninsured deposits
Aclaris Therapeutics Inc. acquired privately held biotechnology company Confluence Life Sciences Inc. for $10 million in cash and 350,000 shares of the company valued at $10 million.
Confluence is focused on the discovery and development of kinase inhibitors to treat inflammatory and immunological disorders and cancer.
